Millstone Evans Group’s VanEck Biotech ETF BBH Stock Holding History

Millstone Evans Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.52K	Hold	37	–	–	﹤0.01%	628
2026 Q1	$6.96K	Hold	37	–	–	﹤0.01%	615
2025 Q4	$7K	Hold	37	–	–	﹤0.01%	604
2025 Q3	$6.13K	Buy	+37	New	+$6.03K	﹤0.01%	603

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millstone Evans Group's BBH Position: Q2 2026 in Review

Millstone Evans Group held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 37 shares worth $7.52K. The position accounts for ﹤0.01% of the portfolio, ranked #628.

Millstone Evans Group first reported a position in BBH in Q3 2025 and has held it in 4 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Millstone Evans Group held 37 shares of VanEck Biotech ETF worth $7.52K as of Q2 2026.
Millstone Evans Group left its VanEck Biotech ETF share count unchanged in Q2 2026.
VanEck Biotech ETF made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #628 holding.
Millstone Evans Group first reported a position in VanEck Biotech ETF in Q3 2025 and has held it in 4 quarters since.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.